VIRALEZE™ Antiviral Nasal Spray

 

assets/uploads/2021-04/Viraleze_double_carton_onebottle_cropped

What is VIRALEZE™ Antiviral Nasal Spray?

VIRALEZE™ is an antiviral nasal spray that contains astodrimer sodium (SPL7013), which has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2, the virus that causes COVID-19.^

^Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro (2021). Antiviral Research: https://doi.org/10.1016/j.antiviral.2021.105089

 

VIRALEZE™ was developed in Australia by Starpharma, a world leader in the development of new medical products based on its proprietary dendrimer technology.

The active in VIRALEZE™, astodrimer sodium (also known as SPL7013), is a patented, precisely designed large molecule that cannot pass into the bloodstream and that acts locally at site of application in the nasal cavity.

Astodrimer sodium is included in products approved in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand. 

VIRALEZE™ is complimentary to other measures such as vaccines, masks, and physical distancing.

VIRALEZE™ is registered for sale in the UK/Europe and India. VIRALEZE™ launched in the UK through LloydsPharmacy, as announced on 25 March 2021 and then in Europe via Starpharma's www.viraleze.co webstore, as announced on 6 May 2021. Starpharma is also progressing regulatory activities for a number of markets, including Australia, with the intention of rolling it out across other markets. VIRALEZE™ is not approved for sale or supply in Australia.

Starpharma was awarded development funding for VIRALEZE™ by the Australian Government’s Medical Research Future Fund Biomedical Translation Bridge Program. 

 

How does VIRALEZE™ work?

 

VIRALEZE™ targets the area in the nasal cavity where respiratory viruses that cause colds, flu and more severe respiratory illness, such as COVID-19, first attach and start to multiply. The nasal cavity is the primary site where SARS-CoV-2 (COVID-19) becomes established, before spreading to the lungs.^

VIRALEZE™ contains astodrimer sodium (SPL7013) which is antiviral and has been shown in laboratory studies to inactivate viruses, adding a further physical barrier to respiratory viruses. 

Viraleze_animation

click here to play video.

^Hou, Y.J., et al. 2020. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182(2), 429-446.e14. https://doi.org/10.1016/j.cell.2020.05.042
†Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro (2021). Antiviral Research: https://doi.org/10.1016/j.antiviral.2021.105089

 

Astodrimer sodium (SPL7013) acts by blocking the interaction between the
SARS-CoV-2 viral “spikes” and the human cells the virus is seeking to infect.

“Spike” proteins on the surface of these (SARS-CoV-2) viruses that come into contact with VIRALEZE™ are trapped by astodrimer sodium. This interaction is “virucidal” – the virus is irreversibly blocked and can no longer infect cells.

This mechanism provides a physical barrier to respiratory viruses in the nasal cavity. The “blocked” viruses are then cleared naturally through the nasal mucus.

†Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro (2021). Antiviral Research: https://doi.org/10.1016/j.antiviral.2021.105089

For more information: 

Download ASX Announcement: VIRALEZE UK update (PDF 320kb) - 21 June 2021

Download ASX Announcement: VIRALEZE SPL7013 virucidal against multiple COVID variants(PDF 520kb) - 18 June 2021

Download ASX Announcement: VIRALEZE antiviral nasal spray registered for sale in India (PDF 520kb) - 11 June 2021

Download ASX Announcement: VIRALEZE SPL7013 highly active in UK variant of coronavirus (PDF 520kb) - 1 June 2021

Download ASX Announcement: VIRALEZE™ launches in Europe (PDF 218kb) - 6 May 2021

Download ASX Announcement: VIRALEZE™ now launched by LloydsPharmacy in the UK (PDF 224kb) - 30 March 2021

Download ASX Announcement: VIRALEZE™ to be launched with LloydsPharmacy in the UK (PDF 241kb) - 25 March 2021

Download ASX Announcement: SPL7013 active against other pandemic coronaviruses (PDF 418kb) - 3 March 2021

Download ASX Announcement: VIRALEZE™ antiviral nasal spray registered in Europe (PDF 226kb) - 23 February 2021

Download full announcement: VIRALEZE COVID-19 nasal spray study to commence in January (PDF 71kb) - 22 December 2020

Download full announcement: VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21 (PDF 113kb) – 10 December 2020

Download full announcement: SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray (PDF 95kb) – 19 November 2020

Download full announcement: SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2 (PDF 183kb) – 14 September 2020

Download full announcement: SPL7013 nasal spray for COVID-19 – development update (PDF 267kb) – 25 August 2020

Download ASX Announcement: SPL7013 shows significant activity against SARS-CoV-2 (coronavirus) (pdf file, 69kb) – 15 April 2020